Humana Inc. (NYSE:HUM) Stake Decreased by BB&T Corp

BB&T Corp reduced its position in shares of Humana Inc. (NYSE:HUM) by 4.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,308 shares of the insurance provider’s stock after selling 169 shares during the period. BB&T Corp’s holdings in Humana were worth $796,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America increased its position in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after buying an additional 4 shares during the period. Creative Planning increased its position in shares of Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after buying an additional 15 shares during the period. Sit Investment Associates Inc. increased its position in shares of Humana by 0.3% in the second quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after buying an additional 40 shares during the period. AE Wealth Management LLC increased its position in shares of Humana by 3.8% in the first quarter. AE Wealth Management LLC now owns 1,305 shares of the insurance provider’s stock worth $269,000 after buying an additional 48 shares during the period. Finally, Howard Hughes Medical Institute increased its position in shares of Humana by 6.2% in the first quarter. Howard Hughes Medical Institute now owns 1,178 shares of the insurance provider’s stock worth $243,000 after buying an additional 69 shares during the period. 99.66% of the stock is owned by institutional investors and hedge funds.

Humana Inc. (NYSE HUM) traded up 0.01% during mid-day trading on Tuesday, hitting $249.65. The company’s stock had a trading volume of 92,417 shares. Humana Inc. has a 52-week low of $163.50 and a 52-week high of $251.79. The company’s 50 day moving average is $236.19 and its 200-day moving average is $220.68. The stock has a market cap of $36.08 billion, a P/E ratio of 20.54 and a beta of 0.91.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. The firm had revenue of $13.53 billion during the quarter, compared to analyst estimates of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter in the prior year, the company posted $2.30 earnings per share. On average, equities analysts predict that Humana Inc. will post $11.45 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/08/08/bbt-corp-sells-169-shares-of-humana-inc-nysehum-updated.html.

HUM has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $256.00 price objective for the company in a research note on Monday, May 8th. Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a research note on Friday, June 9th. BidaskClub downgraded Humana from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Cantor Fitzgerald upped their price objective on Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Wednesday, April 26th. Finally, Citigroup Inc. assumed coverage on Humana in a research note on Wednesday, June 28th. They issued a “buy” rating and a $275.00 price objective for the company. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $243.00.

In other news, VP Heidi S. Margulis sold 1,500 shares of the company’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the completion of the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at $1,890,474. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of the company’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply